Updates are available Correction dated 2022-10-04
Click to view Correction: https://doi.org/10.1038/s41591-022-02070-0
-
Authors
Feigin, Andrew
Evans, Elizabeth E. https://orcid.org/0000-0002-9287-9221
Fisher, Terrence L. https://orcid.org/0000-0001-9326-6606
Leonard, John E. https://orcid.org/0000-0003-2154-750X
Smith, Ernest S.
Reader, Alisha
Mishra, Vikas https://orcid.org/0000-0002-4555-0132
Manber, Richard
Walters, Kimberly A. https://orcid.org/0000-0002-2699-0124
Kowarski, Lisa https://orcid.org/0000-0003-2392-0494
Oakes, David
Siemers, Eric
Kieburtz, Karl D.
Zauderer, Maurice https://orcid.org/0000-0002-4253-9165
,
Kayson, Elise
Goldstein, Jody
Barbano, Richard
Marder, Karen
Dayalu, Praveen
Rosas, Herminia Diana
Kostyk, Sandra
Kamholz, John
Racette, Brad
Bang, Jee
Claassen, Daniel
McDonell, Katherine
Factor, Stewart
Walker, Francis
Goas, Clarisse
Wojcieszek, Joanne
Raymond, Lynn A.
Corey-Bloom, Jody
Sung, Victor
Dean, Marissa
Geshwind, Michael
Nelson, Alexandra
Frank, Samuel
LaFaver, Kathrin
Duker, Andrew
Elmer, Lawrence
Samii, Ali
Lin, Yi-Han
Chouinard, Sylvain
Seeberger, Lauren
Scott, Burton
Boyd, James
McFarland, Nikolaus
Stimming, Erin Furr
Suchowersky, Oksana
Testa, Claudia
Anderson, Karen
-
Funding
Funding for this research was provided by:
Vaccinex, Inc. Internal Research
- License Information
-
More Information
Article History
Received: 7 December 2021
Accepted: 27 June 2022
First Online: 8 August 2022
Change Date: 4 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-02070-0
Competing interests
: Vaccinex employment and stock: E.E.E., T.L.F., J.E.L., E.S., V.M. and M.Z. Vaccinex patents and applications related to SEMA4D (USPTO nos. 8,816,058, 9,090,709, 10,800,853 and 7,919,594): E.E.E., T.L.F., E.S. and M.Z. IXICO employment and stock: R.M. Research grant support from HSG, Neurocrine, Uniqure and Vaccinex: P.D. Payments to Clintrex Research Corporation for provision of research services during the conduct of the trial: K.D.K. Research funding from Vaccinex, CHDI, HDSA, Roche/Genentech, UniQure, HSG/NBI and Cures within Reach, consulting role for Teva and on Speaker’s Bureau of Sunovion Pharmaceuticals: E.F.S. Consultation fees from Amylyz, Novartis, Sage, Teva and Uniqure, grant funding from uniQure, Roche/Genentech, Triplet Therapeutics and CHDI and salary support from HSG for serving as chair of DSMB of a study funded by Neurocrine and the virtual UHDRS study: S. Frank. The remaining authors declare no competing interests.
